Materiały źródłowe

• #1 Wet Age-Related Macular Degeneration (AMD) – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK572147/

  Wet (exudative or neovascular) age-related macular degeneration is the most common cause of visual impairment among older patients in developed countries. Approximately 10% of patients with age-related macular degeneration develop choroidal neovascularization, which is the hallmark of wet age-related macular degeneration. Vascular endothelial growth factor plays a critical role in the development of choroidal neovascularization, leading to complications such as bleeding under the retina, retinal pigment epithelium detachment or atrophy, hard exudate deposition, or subretinal or subretinal pigment epithelium fluid accumulation with associated vision loss. […] Wet age-related macular degeneration diagnosis relies on clinical examination and imaging techniques. Fundus examination may show retinal hemorrhages or exudates, whereas optical coherence tomography offers detailed images of retinal structure and fluid. Fluorescein angiography helps confirm neovascularization by visualizing dye leakage from retinal blood vessels.

• #2 Exudative (Wet) Age-Related Macular Degeneration (AMD): Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1226030-overview

  In the wet, or exudative, form of age-related macular degeneration (AMD or ARMD), pathologic choroidal neovascular membranes (CNVM) develop under the retina. The CNVM can leak fluid and blood and, if left untreated, ultimately cause a centrally blinding disciform scar. Approximately 10% of patients with nonexudative AMD eventually progress to the exudative form, which is responsible for the majority of the estimated 1.75 million cases of advanced AMD in the United States. […] AMD is the leading cause of irreversible visual loss in the United States, with variable degrees of age-related macular changes occurring in 19.8 million (12.6%) of the population aged 40 years and older in 2019. Just under 1% (1.49 million) of these had vision-threatening illness. The prevalence of AMD rose with age from 2% among individuals aged 40 to 44 years to 46.6% among persons aged 85 years and older. Approximately 10% of patients with nonexudative AMD progress to the exudative form. Thus, severe vision loss in many of the at least 1.75 million individuals who currently have advanced AMD is secondary to the effects of CNV from AMD. The overall prevalence of advanced AMD (geographic atrophy and/or CNV) is expected to increase from 2 million individuals in 2020 to 5.44 million individuals in 2050.

• #3 Wet Age-Related Macular Degeneration (AMD) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/133116

  Wet age-related macular degeneration (AMD), also known as exudative or neovascular AMD, primarily affects the macula and is the most common cause of central visual impairment and blindness among older individuals in developed countries. […] In 2015, AMD was the third most common cause of moderate-to-severe visual impairment worldwide. The global prevalence of AMD among individuals aged 45 to 85 was 8.7%, with a prevalence of 0.4% for advanced AMD. […] Approximately 10% to 15% of patients with AMD develop neovascular disease. […] In the absence of anti-VEGF therapy, around 79% to 90% of affected eyes eventually become legally blind due to complications from neovascularization. […] The global prevalence of any AMD stage is predicted to increase from 196 million people in 2020 to 288 million by 2040.

• #4 Genentech: About AMD

  https://www.gene.com/patients/disease-education/amd-fact-sheet

  Macular degeneration results from damage to the macula, the part of the eye responsible for central vision and the ability to see fine details clearly. Most cases of macular degeneration occur as part of the aging process and are known as age-related macular degeneration (AMD). AMD is a progressive retinal disease with multiple environmental and genetic risk factors. […] AMD is a leading cause of irreversible blindness or vision loss in people over 60, if left untreated. There are two forms of AMD – dry and wet. All cases begin as the dry form, but 10 percent to 15 percent progress to the wet form, which can result in sudden and severe central vision loss. […] Wet AMD accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. Wet, or neovascular, AMD is an advanced form of the condition that can cause rapid and severe vision loss. Wet AMD involves the uncontrolled growth of new blood vessels in the back of the eye, resulting in leakage of fluid into the macula. […] About 200,000 new cases of wet AMD are diagnosed each year in North America.

• #5 Moran CORE | Wet versus Dry Macular Degenerative Changes

  https://morancore.utah.edu/basic-ophthalmology-review/wet-versus-dry-macular-degenerative-changes/

  Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in industrialized countries among people 50 years or older. […] The risk of progressing from dry AMD to wet AMD is estimated at 1 to 4.7 percent in one year and 13 to 18 percent at three years. […] Wet AMD is less common than dry AMD, affecting only 10 to 15 percent of people with AMD. However, it accounts for more than 80% of patients with severe visual loss or legal blindness. […] The goal is to recognize these new vessels before they bleed and cause a hemorrhagic detachment of the retinal pigment epithelium. […] To prevent this progression, patients can be advised to stop smoking and take a combination of vitamins and minerals that make up the AREDS formula (Age-Related Eye Disease Study). […] By inhibiting VEGF, the progression of wet AMD is stopped and vision loss can be stabilized or improved.

• #6 Wet Age-Related Macular Degeneration (AMD) – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK572147/

  This activity for healthcare professionals is designed to enhance learners’ competence in evaluating and managing wet age-related macular degeneration. […] In 2015, AMD was the third most common cause of moderate-to-severe visual impairment worldwide. The global prevalence of AMD among individuals aged 45 to 85 was 8.7%, with a prevalence of 0.4% for advanced AMD. […] Approximately 10% to 15% of patients with AMD develop neovascular disease. […] AMD is differentiated from early or dry AMD by the presence of CNV, where new blood vessels from the choroid penetrate through the Bruch membrane and proliferate either between the Bruch membrane and the RPE or in the subretinal space. […] The mainstay of therapy for wet AMD is intravitreal anti-VEGF treatment. Currently used agents prevent visual loss and may also improve vision in some cases. […] Several emerging therapies for wet AMD are currently under investigation. These treatments aim to improve existing options by exploring new mechanisms, delivery systems, and formulations to enhance efficacy and reduce treatment burden.

• #7 Wet Age-Related Macular Degeneration (AMD) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/133116

  Wet age-related macular degeneration (AMD), also known as exudative or neovascular AMD, primarily affects the macula and is the most common cause of central visual impairment and blindness among older individuals in developed countries. […] In 2015, AMD was the third most common cause of moderate-to-severe visual impairment worldwide. The global prevalence of AMD among individuals aged 45 to 85 was 8.7%, with a prevalence of 0.4% for advanced AMD. […] Approximately 10% to 15% of patients with AMD develop neovascular disease. […] In the absence of anti-VEGF therapy, around 79% to 90% of affected eyes eventually become legally blind due to complications from neovascularization. […] The global prevalence of any AMD stage is predicted to increase from 196 million people in 2020 to 288 million by 2040.

• #8 Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9595233/

  The greatest global root of irremediable amaurosis in the venerable is age-related macular degeneration (AMD), a complex eye condition. […] In the urbanized, industrialized world, age-related macular degeneration (AMD) is one of the major causes of central vision loss in the older age group. […] Age-related macular degeneration (AMD) affects one in eight people 60 years of age or older and is the most common cause of irreversible blindness in older persons in developed countries. […] According to thorough estimates, 200 million people worldwide are estimated to have AMD, and by 2040, this number is projected to rise to close to 300 million. […] Neovascular age-related macular degeneration (nAMD), one of the most common causes of blindness, affects more than 200 million people worldwide.

• #9 Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9595233/

  The greatest global root of irremediable amaurosis in the venerable is age-related macular degeneration (AMD), a complex eye condition. […] In the urbanized, industrialized world, age-related macular degeneration (AMD) is one of the major causes of central vision loss in the older age group. […] Age-related macular degeneration (AMD) affects one in eight people 60 years of age or older and is the most common cause of irreversible blindness in older persons in developed countries. […] According to thorough estimates, 200 million people worldwide are estimated to have AMD, and by 2040, this number is projected to rise to close to 300 million. […] Neovascular age-related macular degeneration (nAMD), one of the most common causes of blindness, affects more than 200 million people worldwide.

• #10 Wet Age-Related Macular Degeneration (AMD) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/133116

  Wet age-related macular degeneration (AMD), also known as exudative or neovascular AMD, primarily affects the macula and is the most common cause of central visual impairment and blindness among older individuals in developed countries. […] In 2015, AMD was the third most common cause of moderate-to-severe visual impairment worldwide. The global prevalence of AMD among individuals aged 45 to 85 was 8.7%, with a prevalence of 0.4% for advanced AMD. […] Approximately 10% to 15% of patients with AMD develop neovascular disease. […] In the absence of anti-VEGF therapy, around 79% to 90% of affected eyes eventually become legally blind due to complications from neovascularization. […] The global prevalence of any AMD stage is predicted to increase from 196 million people in 2020 to 288 million by 2040.

• #11 Age-Related Macular Degeneration (AMD) | Bayer Global

  https://www.bayer.com/en/pharma/age-related-macular-degeneration-amd

  In age-related macular degeneration, the nerve cells are destroyed in the macula – the point of sharpest vision on the retina. This is caused by deposits beneath the retina as a result of local disturbances in retina metabolism. […] Age-related macular degeneration – the most common cause of blindness in people over 65. As you grow older, you become more experienced, knowledgeable, wise and farsighted. However, an estimated 170 million people live with age-related macular degeneration (AMD) globally, which is the most common cause of severe visual impairment and blindness among people over the age of 65 in developed countries. […] As societies continue to age, the incidence of age-related macular degeneration is projected to increase even further to 288 million people worldwide by 2040, with women more frequently affected than men.

• #12 Prevalence of Age-related Macular Degeneration (AMD) – Prevent Blindness

  https://preventblindness.org/amd-prevalence-vehss/

  A 2022 study found that, in 2019, an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD). This is an increase of approximately more than 2.75 times previous estimates (which used a more conservative definition of early AMD based on larger drusen size). […] An estimated 18.34 million Americans had early AMD and 1.49 million had the late stage vision threatening form of AMD (late AMD included geographic atrophy in this study). […] Approximately one in 10 Americans aged 50 and older have the early form of AMD and approximately 1 out of every 100 Americans ages 50 and older have the vision threatening late form of AMD. […] Among persons aged 80 and older, approximately 3 in 10 had early AMD, and approximately 1 and 10 have the vision threatening late form of AMD.

• #13 Prevalence of Age-related Macular Degeneration (AMD) – Prevent Blindness

  https://preventblindness.org/amd-prevalence-vehss/

  A 2022 study found that, in 2019, an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD). This is an increase of approximately more than 2.75 times previous estimates (which used a more conservative definition of early AMD based on larger drusen size). […] An estimated 18.34 million Americans had early AMD and 1.49 million had the late stage vision threatening form of AMD (late AMD included geographic atrophy in this study). […] Approximately one in 10 Americans aged 50 and older have the early form of AMD and approximately 1 out of every 100 Americans ages 50 and older have the vision threatening late form of AMD. […] Among persons aged 80 and older, approximately 3 in 10 had early AMD, and approximately 1 and 10 have the vision threatening late form of AMD.

• #14 Prevalence of Age-related Macular Degeneration (AMD) – Prevent Blindness

  https://preventblindness.org/amd-prevalence-vehss/

  A 2022 study found that, in 2019, an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD). This is an increase of approximately more than 2.75 times previous estimates (which used a more conservative definition of early AMD based on larger drusen size). […] An estimated 18.34 million Americans had early AMD and 1.49 million had the late stage vision threatening form of AMD (late AMD included geographic atrophy in this study). […] Approximately one in 10 Americans aged 50 and older have the early form of AMD and approximately 1 out of every 100 Americans ages 50 and older have the vision threatening late form of AMD. […] Among persons aged 80 and older, approximately 3 in 10 had early AMD, and approximately 1 and 10 have the vision threatening late form of AMD.

• #15 VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html

  The Vision and Eye Health Surveillance System (VEHSS) prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] VEHSS researchers used a statistical method called Bayesian meta-regression to combine information from multiple data sources to produce AMD prevalence estimates among the entire US population in 2019. […] AMD in either eye. […] Vision threatening AMD: geographic atrophy or exudative AMD (includes wet-form AMD or choroidal neovascularization) in either eye. […] In 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). […] Of these, 1.49 million (0.94%) were living with vision threatening. […] Prevalence of AMD increased with age from 2% (95% Uncertainty Interval [UI]: 1.3 to 2.9) among people aged 40 to 44 to 46.6% (95% UI: 28.4 to 72.4) among people aged 85.

• #16 VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html

  The Vision and Eye Health Surveillance System (VEHSS) prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] VEHSS researchers used a statistical method called Bayesian meta-regression to combine information from multiple data sources to produce AMD prevalence estimates among the entire US population in 2019. […] AMD in either eye. […] Vision threatening AMD: geographic atrophy or exudative AMD (includes wet-form AMD or choroidal neovascularization) in either eye. […] In 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). […] Of these, 1.49 million (0.94%) were living with vision threatening. […] Prevalence of AMD increased with age from 2% (95% Uncertainty Interval [UI]: 1.3 to 2.9) among people aged 40 to 44 to 46.6% (95% UI: 28.4 to 72.4) among people aged 85.

• #17 Exudative (Wet) Age-Related Macular Degeneration (AMD): Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1226030-overview

  In the wet, or exudative, form of age-related macular degeneration (AMD or ARMD), pathologic choroidal neovascular membranes (CNVM) develop under the retina. The CNVM can leak fluid and blood and, if left untreated, ultimately cause a centrally blinding disciform scar. Approximately 10% of patients with nonexudative AMD eventually progress to the exudative form, which is responsible for the majority of the estimated 1.75 million cases of advanced AMD in the United States. […] AMD is the leading cause of irreversible visual loss in the United States, with variable degrees of age-related macular changes occurring in 19.8 million (12.6%) of the population aged 40 years and older in 2019. Just under 1% (1.49 million) of these had vision-threatening illness. The prevalence of AMD rose with age from 2% among individuals aged 40 to 44 years to 46.6% among persons aged 85 years and older. Approximately 10% of patients with nonexudative AMD progress to the exudative form. Thus, severe vision loss in many of the at least 1.75 million individuals who currently have advanced AMD is secondary to the effects of CNV from AMD. The overall prevalence of advanced AMD (geographic atrophy and/or CNV) is expected to increase from 2 million individuals in 2020 to 5.44 million individuals in 2050.

• #18 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  In the case of the United States, as per estimates, approximately 11 to 15 million people in the United States have AMD, and more than 1.7 million Americans have the advanced form of the disease. About 200,000 new cases of wet AMD are diagnosed each year in North America. Due to the aging population, the National Eye Institute estimates that the prevalence of advanced AMD will grow to nearly 3 million by 2020. […] Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. This assumption was particularly used to obtain the burden of Wet-AMD among the prevalent AMD population. Age is a prominent risk factor for Age-related macular degeneration. The risk of getting advanced age-related macular degeneration increase from 2% for those ages 50-59 to nearly 30% for those over the age of 75.

• #19 Genentech: About AMD

  https://www.gene.com/patients/disease-education/amd-fact-sheet

  Macular degeneration results from damage to the macula, the part of the eye responsible for central vision and the ability to see fine details clearly. Most cases of macular degeneration occur as part of the aging process and are known as age-related macular degeneration (AMD). AMD is a progressive retinal disease with multiple environmental and genetic risk factors. […] AMD is a leading cause of irreversible blindness or vision loss in people over 60, if left untreated. There are two forms of AMD – dry and wet. All cases begin as the dry form, but 10 percent to 15 percent progress to the wet form, which can result in sudden and severe central vision loss. […] Wet AMD accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. Wet, or neovascular, AMD is an advanced form of the condition that can cause rapid and severe vision loss. Wet AMD involves the uncontrolled growth of new blood vessels in the back of the eye, resulting in leakage of fluid into the macula. […] About 200,000 new cases of wet AMD are diagnosed each year in North America.

• #20 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  A recent study by the European Eye Epidemiology (E3) Consortium collated prevalence data of 14 European population studies and reported the prevalence of any AMD among adults aged 70 years and older to be 16.2% based on the Rotterdam classification. The authors extrapolated the number of Europeans with early and late AMD and predicted almost a doubling of AMD prevalence in Europe until 2040. Yet, until today, we lack pooled European estimates on AMD incidence. […] The total prevalent cases of Wet-AMD patients are increasing in 7MM during the study period, i.e., 2017-2030. […] The disease epidemiology covered in the report provides historical as well as forecasted Wet-AMD symptoms epidemiology segmented as the Total Prevalent cases of Wet-AMD, Gender-specific cases of Wet-AMD, and Age-specific cases of Wet-AMD. The report includes the prevalent scenario of Wet-AMD symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

• #21 Age-related macular degeneration (AMD) | CERAAge-related macular degeneration (AMD) | CERA

  https://www.cera.org.au/conditions/amd/

  In age-related macular degeneration (AMD), the cells responsible for central vision die away and bleeding can occur. This causes progressive vision loss in the later stages of the disease. […] AMD is an eye disease that affects the macula – the central part of the retina at the back of the eye. The macula is full of light-sensitive cells that give us sharp central vision when we look straight ahead. […] Wet AMD – also known as neovascular AMD – is caused by abnormal blood vessels that grow under the retina and bleed. It is often more sudden and noticeable than dry AMD. […] AMD is the leading cause of legal blindness in Australia. Nearly one in 15 Australians over the age of 80 has late-AMD. […] If the early signs of AMD are found, you will need to have your eyes checked more than usual. That way, if the disease does progress to the ‘wet’ form of late AMD, steps can be taken straight away to help treat it and save your sight.

• #22 About Age-Related Macular Degeneration | Macular Disease Foundation Australia

  https://www.mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/amd-overview/

  Approximately one in seven Australians over the age of 50 have some evidence of AMD. […] AMD is responsible for half of all blindness and severe vision loss in this country. […] About 17 per cent of these people will experience vision impairment. […] Almost 15 per cent of Australians aged over 80 have vision loss or blindness from age-related macular degeneration. […] Age is the single biggest risk factor for AMD. […] The only way to diagnose AMD in the early stages is through an eye examination, including a check of the macula. […] Early detection of age-related macular degeneration is crucial to saving sight. […] There is effective treatment in the form of eye injections for wet (neovascular) age-related macular degeneration. […] Researchers from Australia and around the world are looking for ways to cure AMD.

• #23 Age-related Macular Degeneration in Asia – Retina Today

  https://retinatoday.com/articles/2009-sept/0909_06-php

  Age-related macular degeneration (AMD) is a major cause of blindness in the elderly in Asian countries, and the number is growing significantly. This may be due to the urbanization of Asian populations, Westernization of lifestyles, and increasing disease awareness. […] The perception that AMD is much less common in Asians than in whites may no longer be true with increasing evidence from recent population-based studies. […] The Hisayama Study in Japan reported that, in a Japanese population aged 50 years of age or older, the prevalence of early AMD was 12.7% and late AMD was 0.87%. […] The frequency of neovascular AMD was significantly higher in the men. […] The overall impression was that the prevalence of AMD in Asians is not greatly different from that in whites. […] Future research in Asia will begin to evaluate incidence and risk factors.

• #24 Age-related Macular Degeneration in Asia – Retina Today

  https://retinatoday.com/articles/2009-sept/0909_06-php

  Age-related macular degeneration (AMD) is a major cause of blindness in the elderly in Asian countries, and the number is growing significantly. This may be due to the urbanization of Asian populations, Westernization of lifestyles, and increasing disease awareness. […] The perception that AMD is much less common in Asians than in whites may no longer be true with increasing evidence from recent population-based studies. […] The Hisayama Study in Japan reported that, in a Japanese population aged 50 years of age or older, the prevalence of early AMD was 12.7% and late AMD was 0.87%. […] The frequency of neovascular AMD was significantly higher in the men. […] The overall impression was that the prevalence of AMD in Asians is not greatly different from that in whites. […] Future research in Asia will begin to evaluate incidence and risk factors.

• #25 About Age-Related Macular Degeneration | Macular Disease Foundation Australia

  https://www.mdfoundation.com.au/about-macular-disease/age-related-macular-degeneration/amd-overview/

  Approximately one in seven Australians over the age of 50 have some evidence of AMD. […] AMD is responsible for half of all blindness and severe vision loss in this country. […] About 17 per cent of these people will experience vision impairment. […] Almost 15 per cent of Australians aged over 80 have vision loss or blindness from age-related macular degeneration. […] Age is the single biggest risk factor for AMD. […] The only way to diagnose AMD in the early stages is through an eye examination, including a check of the macula. […] Early detection of age-related macular degeneration is crucial to saving sight. […] There is effective treatment in the form of eye injections for wet (neovascular) age-related macular degeneration. […] Researchers from Australia and around the world are looking for ways to cure AMD.

• #26 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  In the case of the United States, as per estimates, approximately 11 to 15 million people in the United States have AMD, and more than 1.7 million Americans have the advanced form of the disease. About 200,000 new cases of wet AMD are diagnosed each year in North America. Due to the aging population, the National Eye Institute estimates that the prevalence of advanced AMD will grow to nearly 3 million by 2020. […] Wet macular degeneration accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. This assumption was particularly used to obtain the burden of Wet-AMD among the prevalent AMD population. Age is a prominent risk factor for Age-related macular degeneration. The risk of getting advanced age-related macular degeneration increase from 2% for those ages 50-59 to nearly 30% for those over the age of 75.

• #27 Age Related Macular Degeneration | Wet AMD | Non-Neovascular Macular Degeneration

  https://www.retinacenternj.com/diseases-treatment/age-related-macular-degeneration-wet-amd-or-non-ne

  Age Related Macular Degeneration (ARMD) is classified into stages according to disease presentation and clinical findings. […] Stage 4 Advanced ARMD (Wet ARMD and Dry ARMD with GA) is the leading cause of legal blindness in the US in patients over 70. The total number of people with Stage 4 Advanced ARMD is projected to rise from 285 million in 2010 to 439 million in 2030. Stage 4 Advanced ARMD is responsible for 1.8 million of the 37 million cases of blindness throughout the world. Stage 4 Advanced ARMD is the 3rd Leading cause of blindness worldwide behind only cataracts and glaucoma. […] The best predictor of development of ARMD is the age of the patient: Age 60 – 69 = 5% to 10% incidence of ARMD Age 70 – 79 = 10% – 20% incidence of ARMD Age 80 – 89 = 30% – 40% incidence of ARMD Age 90 – 99 = 50% – 70% incidence of ARMD Age 100 and above = 80% – 100% incidence of ARMD.

• #28 Age Related Macular Degeneration | Wet AMD | Non-Neovascular Macular Degeneration

  https://www.retinacenternj.com/diseases-treatment/age-related-macular-degeneration-wet-amd-or-non-ne

  Age Related Macular Degeneration (ARMD) is classified into stages according to disease presentation and clinical findings. […] Stage 4 Advanced ARMD (Wet ARMD and Dry ARMD with GA) is the leading cause of legal blindness in the US in patients over 70. The total number of people with Stage 4 Advanced ARMD is projected to rise from 285 million in 2010 to 439 million in 2030. Stage 4 Advanced ARMD is responsible for 1.8 million of the 37 million cases of blindness throughout the world. Stage 4 Advanced ARMD is the 3rd Leading cause of blindness worldwide behind only cataracts and glaucoma. […] The best predictor of development of ARMD is the age of the patient: Age 60 – 69 = 5% to 10% incidence of ARMD Age 70 – 79 = 10% – 20% incidence of ARMD Age 80 – 89 = 30% – 40% incidence of ARMD Age 90 – 99 = 50% – 70% incidence of ARMD Age 100 and above = 80% – 100% incidence of ARMD.

• #29 Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9595233/

  The two primary kinds of late-stage AMD that might exist are neovascular (also known as wet or exudative) and non-neovascular (also referred to as atrophic, dry, or non-exudative) AMD. […] AMD prevalence varies greatly by ethnicity, with non-Hispanic White Europeans carrying the majority of the disease burden. […] Neovascular age-related macular degeneration (AMD), sometimes known as wet AMD, is an advanced type of AMD characterized by choroidal neovascularization (CNV), in which newly created blood vessels leak into the retina, producing distortion and fast loss of vision. […] Age-related macular degeneration with neovascularization is a prevalent cause of vision loss worldwide. […] The pathogenesis of AMD includes oxidative stress and retinal inflammatory pathways. […] The assessment of visual impairment linked to AMD manifestations requires the establishment of valid functional endpoints in addition to the structural examination of alterations.

• #30 Macular degeneration – Wikipedia

  https://en.wikipedia.org/wiki/Macular_degeneration

  Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Macular degeneration typically occurs in older people, and is caused by damage to the macula of the retina. The late type is additionally divided into „dry” and „wet” forms, with the dry form making up 90% of cases. In wet-form AMD, blood vessels grow under the macula, causing blood and fluid to leak into the retina. In the wet form, antivascular endothelial growth factor injected into the eye or, less commonly, laser coagulation or photodynamic therapy may slow worsening. Age-related macular degeneration is a main cause of central blindness among the working-aged population worldwide. The prevalence of any age-related macular degeneration is higher in Europeans than in Asians and Africans. The incidence of age-related macular degeneration and its associated features increases with age and is low in people 55 years of age. Smoking is the strongest modifiable risk factor.

• #31 Macular degeneration – Wikipedia

  https://en.wikipedia.org/wiki/Macular_degeneration

  Macular degeneration, also known as age-related macular degeneration (AMD or ARMD), is a medical condition which may result in blurred or no vision in the center of the visual field. Macular degeneration typically occurs in older people, and is caused by damage to the macula of the retina. The late type is additionally divided into „dry” and „wet” forms, with the dry form making up 90% of cases. In wet-form AMD, blood vessels grow under the macula, causing blood and fluid to leak into the retina. In the wet form, antivascular endothelial growth factor injected into the eye or, less commonly, laser coagulation or photodynamic therapy may slow worsening. Age-related macular degeneration is a main cause of central blindness among the working-aged population worldwide. The prevalence of any age-related macular degeneration is higher in Europeans than in Asians and Africans. The incidence of age-related macular degeneration and its associated features increases with age and is low in people 55 years of age. Smoking is the strongest modifiable risk factor.

• #32 Age-Related Macular Degeneration – EyeWiki

  https://eyewiki.org/Age-Related_Macular_Degeneration

  A ten pack-year tobacco smoking history is associated with increased development of exudative age-related macular degeneration. […] The complement system is a three-pronged pathway involved in natural and acquired immunity. […] Activation of the complement system results in cellular damage that is central in the pathogenesis of dry and wet forms of AMD, and this is supported by the presence of many complement system proteins within drusen in patients with AMD. […] Smoking cessation, reduction in body mass index, and treatment of hypertension are modifiable risk factors that should be addressed in patients at risk for, or who have various stages of AMD. […] Observation with risk factor modification and nutritional supplementation is the mainstay of treatment for nonexudative AMD. However, current studies are underway to evaluate complement pathway inhibition for the treatment of geographic atrophy in patients with nonexudative AMD though no treatment modality is currently approved by the FDA for the treatment of geographic atrophy. Exudative AMD is managed with more closely spaced examinations and intravitreal injections of anti-VEGF agents or laser treatments.

• #33 Wet Age-Related Macular Degeneration Market Size, 2034

  https://www.imarcgroup.com/wet-age-related-macular-degeneration-market

  Although the cause of Wet Age-Related Macular Degeneration is still largely unknown, age represents an important risk factor for developing Wet AMD. The disease is most common in people over 50 and becomes even more common in their 70s and 80s. Furthermore, smoking doubles the probability of developing wet AMD. In addition to cutting off oxygen to the eyes, researchers have found that smoking may damage cells and make it more difficult for nutrients to reach the eyes through the bloodstream. Other risk factors include gender, race, family history, heart disease, obesity etc. […] IMARC Groups new report „Wet Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast” provides an exhaustive analysis of the Wet Age-Related Macular Degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The report provides an in-depth understanding of current and future landscape of the Wet Age-Related Macular Degeneration market. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool for Wet Age-Related Macular Degeneration across the seven major markets. According to the report, the United States has the largest patient pool for Wet Age-Related Macular Degeneration and also represents the largest market for Wet Age-Related Macular Degeneration treatments. Furthermore, the current Wet Age-Related Macular Degeneration treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report.

• #34 Age-Related Macular Degeneration (AMD)

  https://www.webmd.com/eye-health/macular-degeneration/age-related-macular-degeneration-overview

  Age-related macular degeneration (AMD) is an eye disease that may get worse over time. Its the leading cause of serious, permanent vision loss in people older than 50. About 1 in 10 people in the U.S. are affected by the condition. […] AMD is the leading cause of permanent blindness in the industrialized world (more than 170 million people affected globally) and the third cause worldwide. […] People who get wet AMD always have dry AMD first. But those with dry AMD don’t always go on to develop the wet type. […] Wet AMD is always considered late stage. But dry AMD may turn into the wet form during any stage. […] If you have wet AMD, your treatments might include: Anti-angiogenesis drugs. These medications block the creation of blood vessels and leaking from the vessels in your eye that cause wet AMD. […] Studies have shown that Black people with AMD were 23% less likely than White AMD patients to be treated with anti-VEGF shots, the main treatment for dry AMD.

• #35 VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html

  The Vision and Eye Health Surveillance System (VEHSS) prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] VEHSS researchers used a statistical method called Bayesian meta-regression to combine information from multiple data sources to produce AMD prevalence estimates among the entire US population in 2019. […] AMD in either eye. […] Vision threatening AMD: geographic atrophy or exudative AMD (includes wet-form AMD or choroidal neovascularization) in either eye. […] In 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). […] Of these, 1.49 million (0.94%) were living with vision threatening. […] Prevalence of AMD increased with age from 2% (95% Uncertainty Interval [UI]: 1.3 to 2.9) among people aged 40 to 44 to 46.6% (95% UI: 28.4 to 72.4) among people aged 85.

• #36 Case Definitions: Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/case-definitions/age-related-macular-degeneration-amd.html

  The Vision and Eye Health Surveillance System (VEHSS) reports the prevalence of Age-Related Macular Degeneration (AMD) for the following categories based on the method of identification: […] The VEHSS prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] Includes vision threatening advanced stages of AMD including geographic atrophy and/or exudative AMD (alternatively defined as wet-form AMD or choroidal neovascularization) in either eye. […] Diagnosed age-related macular degeneration (AMD) is identified based on the presence of International Classification of Diseases (ICD)-9 and ICD-10 codes in patient claims or electronic health record (EHR) systems. […] Wet-form AMD includes diagnosis codes indicating exudative age-related macular degeneration. […] Geographic atrophy, wet-form AMD, or choroidal neovascularization.

• #37 VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html

  The Vision and Eye Health Surveillance System (VEHSS) prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] VEHSS researchers used a statistical method called Bayesian meta-regression to combine information from multiple data sources to produce AMD prevalence estimates among the entire US population in 2019. […] AMD in either eye. […] Vision threatening AMD: geographic atrophy or exudative AMD (includes wet-form AMD or choroidal neovascularization) in either eye. […] In 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). […] Of these, 1.49 million (0.94%) were living with vision threatening. […] Prevalence of AMD increased with age from 2% (95% Uncertainty Interval [UI]: 1.3 to 2.9) among people aged 40 to 44 to 46.6% (95% UI: 28.4 to 72.4) among people aged 85.

• #38 VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html

  The Vision and Eye Health Surveillance System (VEHSS) prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] VEHSS researchers used a statistical method called Bayesian meta-regression to combine information from multiple data sources to produce AMD prevalence estimates among the entire US population in 2019. […] AMD in either eye. […] Vision threatening AMD: geographic atrophy or exudative AMD (includes wet-form AMD or choroidal neovascularization) in either eye. […] In 2019, an estimated 19.8 million (12.6%) Americans aged 40 and older were living with age-related macular degeneration (AMD). […] Of these, 1.49 million (0.94%) were living with vision threatening. […] Prevalence of AMD increased with age from 2% (95% Uncertainty Interval [UI]: 1.3 to 2.9) among people aged 40 to 44 to 46.6% (95% UI: 28.4 to 72.4) among people aged 85.

• #39 VEHSS Modeled Estimates for Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/prevalence-estimates/amd-prevalence.html

  The VEHSS prevalence estimates of AMD were generated using a statistical modeling approach called Bayesian meta-regression, which is used to combine information from multiple VEHSS data sources into a single summary estimate. […] CDC uses the VEHSS estimate as the primary estimate to assess the percentage of people with AMD in the United States by state, county, and across different age groups, racial and ethnic groups, and sex. […] The VEHSS Composite Estimates of AMD are CDCs estimate of the percentage of US residents who have AMD, where they live, and who they are.

• #40 Case Definitions: Age-Related Macular Degeneration (AMD) | Vision and Eye Health Surveillance System | CDC

  https://www.cdc.gov/vision-health-data/case-definitions/age-related-macular-degeneration-amd.html

  The Vision and Eye Health Surveillance System (VEHSS) reports the prevalence of Age-Related Macular Degeneration (AMD) for the following categories based on the method of identification: […] The VEHSS prevalence estimate of AMD is CDCs primary estimate of the prevalence of AMD in the United States. […] Includes vision threatening advanced stages of AMD including geographic atrophy and/or exudative AMD (alternatively defined as wet-form AMD or choroidal neovascularization) in either eye. […] Diagnosed age-related macular degeneration (AMD) is identified based on the presence of International Classification of Diseases (ICD)-9 and ICD-10 codes in patient claims or electronic health record (EHR) systems. […] Wet-form AMD includes diagnosis codes indicating exudative age-related macular degeneration. […] Geographic atrophy, wet-form AMD, or choroidal neovascularization.

• #41 Wet Age-Related Macular Degeneration (AMD) – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK572147/

  Wet (exudative or neovascular) age-related macular degeneration is the most common cause of visual impairment among older patients in developed countries. Approximately 10% of patients with age-related macular degeneration develop choroidal neovascularization, which is the hallmark of wet age-related macular degeneration. Vascular endothelial growth factor plays a critical role in the development of choroidal neovascularization, leading to complications such as bleeding under the retina, retinal pigment epithelium detachment or atrophy, hard exudate deposition, or subretinal or subretinal pigment epithelium fluid accumulation with associated vision loss. […] Wet age-related macular degeneration diagnosis relies on clinical examination and imaging techniques. Fundus examination may show retinal hemorrhages or exudates, whereas optical coherence tomography offers detailed images of retinal structure and fluid. Fluorescein angiography helps confirm neovascularization by visualizing dye leakage from retinal blood vessels.

• #42 Wet age-related macular degeneration – Macular Society

  https://www.macularsociety.org/macular-disease/macular-conditions/wet-age-related-macular-degeneration/

  Wet age-related macular degeneration (AMD) develops when abnormal blood vessels grow into the macula. These leak blood or fluid which leads to scarring of the macula and rapid loss of central vision. Wet AMD can develop very suddenly, but it can now be treated if caught quickly. Fast referral to a hospital specialist is essential. […] Some optometrists use photography or other imaging to detect early signs of macular degeneration. These might include Optical Coherence Tomography (OCT) scans which create cross-sectional images of the retina. […] If your optometrist suspects you have wet AMD, you should be referred to a retinal specialist at a hospital directly and seen within one to two weeks, and if applicable be treated within two weeks after initial detection. […] Wet AMD can be treated if caught early. Drugs are injected into the eye to stop the growth of the abnormal blood vessels. Following diagnosis people will usually have a loading dose of three injections, once a month for three months. A patient will then be assessed to see if more injections are required.

• #43 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://www.openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  Age-related Macular Degeneration (AMD) is a type of maculopathy that results in irreversible visual impairment among the aged population in developed countries. The advanced stages of AMD are geographical atrophy (dry type) and neovascular AMD (wet type), which lead to progressive and severe vision loss. The late stage of wet AMD is diagnosed by the presence of Choroidal Neovascularization (CNV) identified by Optical Coherence Tomography (OCT) or retinal angiography. Patients with CNV are treated with anti-VEGF (Vascular Endothelial Growth Factor) compounds to inhibit blood vessel growth and thereby reducing vision loss. […] A variety of environmental and genetic related risk factors are associated with increased incidence and progression of AMD. The genetic factors are found in the complement, angiogenic and lipid pathways. However, environmental factors, such as smoking and nutrition, are also major risk factors.

• #44 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://www.openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  Age-related Macular Degeneration (AMD) is a type of maculopathy that results in irreversible visual impairment among the aged population in developed countries. The advanced stages of AMD are geographical atrophy (dry type) and neovascular AMD (wet type), which lead to progressive and severe vision loss. The late stage of wet AMD is diagnosed by the presence of Choroidal Neovascularization (CNV) identified by Optical Coherence Tomography (OCT) or retinal angiography. Patients with CNV are treated with anti-VEGF (Vascular Endothelial Growth Factor) compounds to inhibit blood vessel growth and thereby reducing vision loss. […] A variety of environmental and genetic related risk factors are associated with increased incidence and progression of AMD. The genetic factors are found in the complement, angiogenic and lipid pathways. However, environmental factors, such as smoking and nutrition, are also major risk factors.

• #45 Exudative (Wet) Age-Related Macular Degeneration (AMD): Practice Essentials, Background, Pathophysiology

  https://emedicine.medscape.com/article/1226030-overview

  In the wet, or exudative, form of age-related macular degeneration (AMD or ARMD), pathologic choroidal neovascular membranes (CNVM) develop under the retina. The CNVM can leak fluid and blood and, if left untreated, ultimately cause a centrally blinding disciform scar. Approximately 10% of patients with nonexudative AMD eventually progress to the exudative form, which is responsible for the majority of the estimated 1.75 million cases of advanced AMD in the United States. […] AMD is the leading cause of irreversible visual loss in the United States, with variable degrees of age-related macular changes occurring in 19.8 million (12.6%) of the population aged 40 years and older in 2019. Just under 1% (1.49 million) of these had vision-threatening illness. The prevalence of AMD rose with age from 2% among individuals aged 40 to 44 years to 46.6% among persons aged 85 years and older. Approximately 10% of patients with nonexudative AMD progress to the exudative form. Thus, severe vision loss in many of the at least 1.75 million individuals who currently have advanced AMD is secondary to the effects of CNV from AMD. The overall prevalence of advanced AMD (geographic atrophy and/or CNV) is expected to increase from 2 million individuals in 2020 to 5.44 million individuals in 2050.

• #46 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  AMD occurs primarily in elderly individuals, with a striking increase in late AMD in those 75 years or older. […] As the US population ages, the incidence of late AMD is projected to markedly increase, from 2.07 million in 2010 to 5.44 million by 2050. […] A complex interaction between genetics and environmental factors, such as smoking and diet, affects an individual’s susceptibility to AMD. […] The clinical diagnosis of AMD is typically made during examination of the retina by an eye care provider. […] Monitoring these structural changes is crucial for evaluating the response to anti-VEGF agents. […] The goals of anti-VEGF therapy in neovascular AMD are to achieve excellent functional visual acuity and maintain a dry macula on clinical and OCT examination. […] Two approaches—treat-and-extend (TE) and pro re nata (PRN; as needed)—have been used to reduce the injection burden in stable, nonexudative patients with neovascular AMD.

• #47 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  AMD occurs primarily in elderly individuals, with a striking increase in late AMD in those 75 years or older. […] As the US population ages, the incidence of late AMD is projected to markedly increase, from 2.07 million in 2010 to 5.44 million by 2050. […] A complex interaction between genetics and environmental factors, such as smoking and diet, affects an individual’s susceptibility to AMD. […] The clinical diagnosis of AMD is typically made during examination of the retina by an eye care provider. […] Monitoring these structural changes is crucial for evaluating the response to anti-VEGF agents. […] The goals of anti-VEGF therapy in neovascular AMD are to achieve excellent functional visual acuity and maintain a dry macula on clinical and OCT examination. […] Two approaches—treat-and-extend (TE) and pro re nata (PRN; as needed)—have been used to reduce the injection burden in stable, nonexudative patients with neovascular AMD.

• #48 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  Age-related Macular Degeneration (AMD) is a type of maculopathy that results in irreversible visual impairment among the aged population in developed countries. […] The advanced stages of AMD are geographical atrophy (dry type) and neovascular AMD (wet type), which lead to progressive and severe vision loss. […] The late stage of wet AMD is diagnosed by the presence of Choroidal Neovascularization (CNV) identified by Optical Coherence Tomography (OCT) or retinal angiography. […] In recent decades, numerous studies have been conducted on the epidemiology of AMD. […] Epidemiological surveys among populations with diverse ethnicities represent varied prevalence of AMD. […] Klein et al. estimated that in the United States, the incidence of AMD in the elderly will rise significantly from 8% in 2005 to 54% in 2025.

• #49 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://www.openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  In recent decades, numerous studies have been conducted on the epidemiology of AMD. Congdon et al. have estimated that 54% of the older white population that was legally blind in the United States suffered from AMD. […] Epidemiological surveys among populations with diverse ethnicities represent varied prevalence of AMD. […] Klein et al. estimated that in the United States, the incidence of AMD in the elderly will rise significantly from 8% in 2005 to 54% in 2025. […] During a five-year study in Australia, the incidences of early AMD among people younger than 60 years and more than 80 years were estimated to be 13% and 20%, respectively.

• #50 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  During a five-year study in Australia, the incidences of early AMD among people younger than 60 years and more than 80 years were estimated to be 13% and 20%, respectively. […] The advanced levels of AMD are categorized into two forms: non-neovascular (dry, non-exudative or geographical) and neovascular (wet or exudative) AMD. […] In wet-type AMD, choroidal neovascularization leads to subretinal leakage of blood, lipids, fluids, and formation of fibrous scars. […] In spite of significant advancements associated with diagnostic and treatment methods of AMD, further investigations are needed to identify effective therapies for dry forms of AMD and reduce the injection frequency of anti-VEGF compounds for wet AMD. […] Although there is no single preventive method, alteration of modifiable risk factors can effectively impede the development of AMD. […] Both genetic and environmental risk factors are influential in the occurrence of AMD.

• #51 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://www.openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  In recent decades, numerous studies have been conducted on the epidemiology of AMD. Congdon et al. have estimated that 54% of the older white population that was legally blind in the United States suffered from AMD. […] Epidemiological surveys among populations with diverse ethnicities represent varied prevalence of AMD. […] Klein et al. estimated that in the United States, the incidence of AMD in the elderly will rise significantly from 8% in 2005 to 54% in 2025. […] During a five-year study in Australia, the incidences of early AMD among people younger than 60 years and more than 80 years were estimated to be 13% and 20%, respectively.

• #52 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com […] DUBLIN–(BUSINESS WIRE)–The „Wet Age – Related Macular Degeneration (Wet AMD) – Epidemiology Forecast to 2030” report has been added to ResearchAndMarkets.com’s offering. […] This 'Wet-Age-related Macular Degeneration (Wet-AMD) – Epidemiology Forecast – 2030′ report delivers an in-depth understanding of the Wet-AMD, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. […] Wet-AMD Epidemiology […] The Wet-AMD epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

• #53 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  The total prevalent cases of Wet-AMD associated in 7MM countries were 4,426,968 in 2020. […] As per the estimates, the United States has the largest prevalent population of Wet-AMD. […] Among the EU5 countries, Germany had the highest prevalent cases of Wet-AMD, followed by Italy. On the other hand, Spain had the lowest prevalent cases with 300,552 cases in 2020. […] 11-year Forecast of Wet-AMD epidemiology […] 7MM Coverage […] Total Diagnosed Prevalent Cases of Wet-AMD […] Prevalent Cases according to segmentation: Gender-specific cases of Wet-AMD […] Prevalent Cases according to segmentation: Age-specific cases of Wet-AMD […] What are the key findings of the Wet-AMD epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?

• #54 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  The total prevalent cases of Wet-AMD associated in 7MM countries were 4,426,968 in 2020. […] As per the estimates, the United States has the largest prevalent population of Wet-AMD. […] Among the EU5 countries, Germany had the highest prevalent cases of Wet-AMD, followed by Italy. On the other hand, Spain had the lowest prevalent cases with 300,552 cases in 2020. […] 11-year Forecast of Wet-AMD epidemiology […] 7MM Coverage […] Total Diagnosed Prevalent Cases of Wet-AMD […] Prevalent Cases according to segmentation: Gender-specific cases of Wet-AMD […] Prevalent Cases according to segmentation: Age-specific cases of Wet-AMD […] What are the key findings of the Wet-AMD epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?

• #55 Wet Age-Related Macular Degeneration (Wet AMD) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  https://www.researchandmarkets.com/reports/5969674/wet-age-related-macular-degeneration-wet-amd?srsltid=AfmBOopa5wqY_0Ey7uQ7XNafq9Jp45d-0zeyipNGvolpSfY-fJp22Y8s

  The 7 major Wet Age-Related Macular Degeneration (Wet AMD) markets reached a value of US$ 8,997.9 Million in 2023. Looking forward, the publisher expects the 7MM to reach US$ 16,864.9 Million by 2034, exhibiting a growth rate (CAGR) of 7.23% during 2023-2034. […] Wet Age-Related Macular Degeneration is an eye disease that destroys the macula, which is part of the retina at the back of the eye. Wet AMD involves the growth of abnormal blood vessels under the macula that leak blood and fluids into layers of the retina, including the macula. […] Although the cause of Wet Age-Related Macular Degeneration is still largely unknown, age represents an important risk factor for developing Wet AMD. The disease is most common in people over 50 and becomes even more common in their 70s and 80s. […] This report „Wet Age-Related Macular Degeneration Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast” provides an exhaustive analysis of the Wet Age-Related Macular Degeneration market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

• #56 Wet Age-Related Macular Degeneration Market Size, 2034

  https://www.imarcgroup.com/wet-age-related-macular-degeneration-market

  The 7 major Wet Age-Related Macular Degeneration (Wet AMD) markets reached a value of US$ 8,997.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 16,864.9 Million by 2034, exhibiting a growth rate (CAGR) of 5.9% during 2024-2034. […] Wet Age-Related Macular Degeneration is an eye disease that destroys the macula, which is part of the retina at the back of the eye. Wet AMD involves the growth of abnormal blood vessels under the macula that leak blood and fluids into layers of the retina, including the macula. The symptoms of wet AMD usually start suddenly and are often severe. If a patient has wet AMD in one eye, its extremely likely that he will also get it in the other eye. With wet AMD, leaked blood and fluids can cause scar tissue to form and damage cells in the retina, damaging the central vision. Wet AMD can cause severe vision loss but does not lead to total blindness since a patient can retain his side vision. Having wet AMD can, however, make it extremely hard for people to do their daily things and can negatively impact the quality of their life.

• #57 Global Wet Age Related Macular Degeneration (Wet AMD) Epidemiology Forecast to 2030 – ResearchAndMarkets.com

  https://www.businesswire.com/news/home/20210407005578/en/Global-Wet-Age-Related-Macular-Degeneration-Wet-AMD-Epidemiology-Forecast-to-2030—ResearchAndMarkets.com

  The total prevalent cases of Wet-AMD associated in 7MM countries were 4,426,968 in 2020. […] As per the estimates, the United States has the largest prevalent population of Wet-AMD. […] Among the EU5 countries, Germany had the highest prevalent cases of Wet-AMD, followed by Italy. On the other hand, Spain had the lowest prevalent cases with 300,552 cases in 2020. […] 11-year Forecast of Wet-AMD epidemiology […] 7MM Coverage […] Total Diagnosed Prevalent Cases of Wet-AMD […] Prevalent Cases according to segmentation: Gender-specific cases of Wet-AMD […] Prevalent Cases according to segmentation: Age-specific cases of Wet-AMD […] What are the key findings of the Wet-AMD epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?

• #58 Age-related Macular Degeneration in Asia – Retina Today

  https://retinatoday.com/articles/2009-sept/0909_06-php

  Age-related macular degeneration (AMD) is a major cause of blindness in the elderly in Asian countries, and the number is growing significantly. This may be due to the urbanization of Asian populations, Westernization of lifestyles, and increasing disease awareness. […] The perception that AMD is much less common in Asians than in whites may no longer be true with increasing evidence from recent population-based studies. […] The Hisayama Study in Japan reported that, in a Japanese population aged 50 years of age or older, the prevalence of early AMD was 12.7% and late AMD was 0.87%. […] The frequency of neovascular AMD was significantly higher in the men. […] The overall impression was that the prevalence of AMD in Asians is not greatly different from that in whites. […] Future research in Asia will begin to evaluate incidence and risk factors.

• #59 Age-Related Macular Degeneration: Epidemiology, Pathophysiology, Diagnosis, and Treatment

  https://pmc.ncbi.nlm.nih.gov/articles/PMC9595233/

  The greatest global root of irremediable amaurosis in the venerable is age-related macular degeneration (AMD), a complex eye condition. […] In the urbanized, industrialized world, age-related macular degeneration (AMD) is one of the major causes of central vision loss in the older age group. […] Age-related macular degeneration (AMD) affects one in eight people 60 years of age or older and is the most common cause of irreversible blindness in older persons in developed countries. […] According to thorough estimates, 200 million people worldwide are estimated to have AMD, and by 2040, this number is projected to rise to close to 300 million. […] Neovascular age-related macular degeneration (nAMD), one of the most common causes of blindness, affects more than 200 million people worldwide.

• #60 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  AMD occurs primarily in elderly individuals, with a striking increase in late AMD in those 75 years or older. […] As the US population ages, the incidence of late AMD is projected to markedly increase, from 2.07 million in 2010 to 5.44 million by 2050. […] A complex interaction between genetics and environmental factors, such as smoking and diet, affects an individual’s susceptibility to AMD. […] The clinical diagnosis of AMD is typically made during examination of the retina by an eye care provider. […] Monitoring these structural changes is crucial for evaluating the response to anti-VEGF agents. […] The goals of anti-VEGF therapy in neovascular AMD are to achieve excellent functional visual acuity and maintain a dry macula on clinical and OCT examination. […] Two approaches—treat-and-extend (TE) and pro re nata (PRN; as needed)—have been used to reduce the injection burden in stable, nonexudative patients with neovascular AMD.

• #61 Age-Related Macular Degeneration (AMD) | Bayer Global

  https://www.bayer.com/en/pharma/age-related-macular-degeneration-amd

  Vision loss significantly impacts a patient’s daily life and is linked to loss of independence, falls, injury, and negatively impacts cognition, mental health, and employment status. […] „Wet” form of macular degeneration (wet AMD), which accounts for about 10 percent of all AMD cases, causes much more serious restrictions to vision. It is caused by tissue fluid and blood seeping from pathologically changed blood vessels into the macula, leading to edemas (swellings caused by fluid accumulations). […] Medicines that inhibit the vascular endothelial growth factor (VEGF) are commonly used today in the treatment of wet age-related macular degeneration (wet AMD). […] Anti-VEGF therapy aims to slow the abnormal growth of new blood vessels in the eye. […] Conventional anti-VEGF treatments require frequent visits to the hospital or an office-based ophthalmologist to receive injections, which can place a significant burden on patients and their carers. […] Treatment options that offer extended treatment intervals have the potential to substantially alleviate the burden of disease.

• #62 Age-Related Macular Degeneration (AMD) | Bayer Global

  https://www.bayer.com/en/pharma/age-related-macular-degeneration-amd

  Vision loss significantly impacts a patient’s daily life and is linked to loss of independence, falls, injury, and negatively impacts cognition, mental health, and employment status. […] „Wet” form of macular degeneration (wet AMD), which accounts for about 10 percent of all AMD cases, causes much more serious restrictions to vision. It is caused by tissue fluid and blood seeping from pathologically changed blood vessels into the macula, leading to edemas (swellings caused by fluid accumulations). […] Medicines that inhibit the vascular endothelial growth factor (VEGF) are commonly used today in the treatment of wet age-related macular degeneration (wet AMD). […] Anti-VEGF therapy aims to slow the abnormal growth of new blood vessels in the eye. […] Conventional anti-VEGF treatments require frequent visits to the hospital or an office-based ophthalmologist to receive injections, which can place a significant burden on patients and their carers. […] Treatment options that offer extended treatment intervals have the potential to substantially alleviate the burden of disease.

• #63 Genentech: About AMD

  https://www.gene.com/patients/disease-education/amd-fact-sheet

  Macular degeneration results from damage to the macula, the part of the eye responsible for central vision and the ability to see fine details clearly. Most cases of macular degeneration occur as part of the aging process and are known as age-related macular degeneration (AMD). AMD is a progressive retinal disease with multiple environmental and genetic risk factors. […] AMD is a leading cause of irreversible blindness or vision loss in people over 60, if left untreated. There are two forms of AMD – dry and wet. All cases begin as the dry form, but 10 percent to 15 percent progress to the wet form, which can result in sudden and severe central vision loss. […] Wet AMD accounts for approximately 10 percent of cases, but results in 90 percent of legal blindness. Wet, or neovascular, AMD is an advanced form of the condition that can cause rapid and severe vision loss. Wet AMD involves the uncontrolled growth of new blood vessels in the back of the eye, resulting in leakage of fluid into the macula. […] About 200,000 new cases of wet AMD are diagnosed each year in North America.

• #64 Wet Age-Related Macular Degeneration (AMD) | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/133116

  Wet age-related macular degeneration (AMD), also known as exudative or neovascular AMD, primarily affects the macula and is the most common cause of central visual impairment and blindness among older individuals in developed countries. […] In 2015, AMD was the third most common cause of moderate-to-severe visual impairment worldwide. The global prevalence of AMD among individuals aged 45 to 85 was 8.7%, with a prevalence of 0.4% for advanced AMD. […] Approximately 10% to 15% of patients with AMD develop neovascular disease. […] In the absence of anti-VEGF therapy, around 79% to 90% of affected eyes eventually become legally blind due to complications from neovascularization. […] The global prevalence of any AMD stage is predicted to increase from 196 million people in 2020 to 288 million by 2040.

• #65 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  The burden of age-related macular degeneration (AMD), a leading cause of vision loss in the elderly population, is poised to increase dramatically as the baby boomer generation ages. […] AMD-attributed blindness has dropped by approximately 50% to 70% since anti-vascular endothelial growth factor (anti-VEGF) medications were introduced 15 years ago. […] Results of real-world studies have recently highlighted that patients with neovascular AMD are often undertreated and, as a result, their visual potential may not be maximized. […] In the 2019 American Society of Retinal Specialists (ASRS) Preferences and Trends Survey, more than 60% of retinal specialists felt that neovascular AMD is undertreated. […] Addressing undertreatment and the huge injection burden of anti-VEGF therapy are unmet needs of patients with neovascular AMD.

• #66

  https://journals.lww.com/ijo/fulltext/2023/71100/prevalence_of_age_related_macular_degeneration_and.18.aspx

  To report a big data analysis of risk and protective factors in patients with AMD, as well as report on the age-adjusted prevalence in a geriatric Indian cohort in a hospital setting. […] Big data analysis from a hospital setting shows that the prevalence of AMD above the age of 60 years is low. More patients with wet AMD present for treatment compared to dry AMD. […] Age-related macular degeneration (AMD) is caused by a series of changes to the macula, typically beginning with build-up of lipoprotein deposits (drusen). […] The economic burden of treatment of AMD in India is estimated to be more than 1.5 billion USD annually, and this does not include indirect costs such as transportation, loss of income, disability support, or the cost of complications from treatments. […] Alternatively, wet AMD can be caused by changes in the structure of choroidal, leading to choroidal neovascularization (CNV). The mainstay of treatment for wet AMD includes anti vascular endothelial growth factor (VEGF) inhibition by intravitreal injections.

• #67 Age-Related Macular Degeneration Major Market Unmet Needs & Drug Forecast to 2031

  https://www.globaldata.com/store/report/age-related-macular-degeneration-major-market-analysis/

  The Age-Related Macular Degeneration (AMD) market sales across the 7MM was $7.36 billion in 2021. Drug sales in the AMD pharmacotherapy market are expected to grow at a compound annual growth rate (CAGR) of more than 14% between 2021 and 2031. An increase in the number of people with AMD, in line with the growth of the global aging population will drive the market growth during the forecast period. […] AMD is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. It is the most common cause of significant irreversible vision loss among the elderly. […] The report provides: Overview of AMD, including epidemiology, symptoms, diagnosis, and disease management. […] Epidemiological Forecast for AMD (2021-2031) […] Total prevalent cases of wet AMD, both sexes, ages 50 years, N, 2021. […] The AMD market is expected to achieve a CAGR of more than 14% during 2021-2031. […] A few of the major players in the Age-Related Macular Degeneration market are Regeneron, Bayer, Roche, Novartis, and AbbVie among others.

• #68 Wet age-related macular degeneration – Macular Society

  https://www.macularsociety.org/macular-disease/macular-conditions/wet-age-related-macular-degeneration/

  Wet age-related macular degeneration (AMD) develops when abnormal blood vessels grow into the macula. These leak blood or fluid which leads to scarring of the macula and rapid loss of central vision. Wet AMD can develop very suddenly, but it can now be treated if caught quickly. Fast referral to a hospital specialist is essential. […] Some optometrists use photography or other imaging to detect early signs of macular degeneration. These might include Optical Coherence Tomography (OCT) scans which create cross-sectional images of the retina. […] If your optometrist suspects you have wet AMD, you should be referred to a retinal specialist at a hospital directly and seen within one to two weeks, and if applicable be treated within two weeks after initial detection. […] Wet AMD can be treated if caught early. Drugs are injected into the eye to stop the growth of the abnormal blood vessels. Following diagnosis people will usually have a loading dose of three injections, once a month for three months. A patient will then be assessed to see if more injections are required.

• #69 Age-Related Macular Degeneration (AMD) | Bayer Global

  https://www.bayer.com/en/pharma/age-related-macular-degeneration-amd

  Vision loss significantly impacts a patient’s daily life and is linked to loss of independence, falls, injury, and negatively impacts cognition, mental health, and employment status. […] „Wet” form of macular degeneration (wet AMD), which accounts for about 10 percent of all AMD cases, causes much more serious restrictions to vision. It is caused by tissue fluid and blood seeping from pathologically changed blood vessels into the macula, leading to edemas (swellings caused by fluid accumulations). […] Medicines that inhibit the vascular endothelial growth factor (VEGF) are commonly used today in the treatment of wet age-related macular degeneration (wet AMD). […] Anti-VEGF therapy aims to slow the abnormal growth of new blood vessels in the eye. […] Conventional anti-VEGF treatments require frequent visits to the hospital or an office-based ophthalmologist to receive injections, which can place a significant burden on patients and their carers. […] Treatment options that offer extended treatment intervals have the potential to substantially alleviate the burden of disease.

• #70 Wet Age-Related Macular Degeneration: Treatment Advances to Reduce the Injection Burden

  https://www.ajmc.com/view/wet-agerelated-macular-degeneration-treatment-advances-to-reduce-the-injection-burden

  The burden of age-related macular degeneration (AMD), a leading cause of vision loss in the elderly population, is poised to increase dramatically as the baby boomer generation ages. […] AMD-attributed blindness has dropped by approximately 50% to 70% since anti-vascular endothelial growth factor (anti-VEGF) medications were introduced 15 years ago. […] Results of real-world studies have recently highlighted that patients with neovascular AMD are often undertreated and, as a result, their visual potential may not be maximized. […] In the 2019 American Society of Retinal Specialists (ASRS) Preferences and Trends Survey, more than 60% of retinal specialists felt that neovascular AMD is undertreated. […] Addressing undertreatment and the huge injection burden of anti-VEGF therapy are unmet needs of patients with neovascular AMD.

• #71 The Diagnosis and Treatment of Age-Related Macular Degeneration (20.07.2020)

  https://di.aerzteblatt.de/int/archive/article/214734

  Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors. In patients with a later stage of AMD, neovascular AMD is 1.4 times more common than geographical atrophy (the final stage of dry late AMD). The rising prevalence figures may be due not only to the aging of the population, but also to better ascertainment through improved diagnosis. The major effect of age on the emergence of AMD is also reflected in the fact that persons under age 50 generally display very few of the typical changes of AMD, or none at all. The exudative form of late AMD is usually associated with much more rapidly progressive loss of vision than the atrophic form. The visual loss in the exudative form is explained by the development of choroidal neovascularization (CNV) in the macular area. The introduction, in 2005, of an effective treatment for the most aggressive form of AMD, the exudative late form, has led to a stagnation, or even a decrease, in the rates of blindness and severe visual impairment, even though the prevalence of AMD has measurably risen. In 2006, after the publication of two successful phase 3 clinical trials, the journal Science listed anti-VEGF therapy for exudative macular degeneration as one of the top ten scientific breakthroughs of the year. In this form of treatment, an anti-VEGF drug is injected directly in the vitreous body of the eye (intravitreal administration). Although the various anti-VEGF drugs differ from one another, they share a common mechanism of action, i.e., the blocking of vascular endothelial growth factor (VEGF). Much of the effect of VEGF inhibitors against wet macular degeneration comes from the reduction of vessel permeability, rather than from the inhibition of angiogenesis. AMD is a chronic disease in which the responsible pathogenetic-mechanistic cascade cannot be brought to a standstill with causally directed treatment early on in the course of illness, even in the stages for which effective treatment is available.

• #72 The Diagnosis and Treatment of Age-Related Macular Degeneration (20.07.2020)

  https://di.aerzteblatt.de/int/archive/article/214734

  Age-related macular degeneration (AMD) is thought to cause approximately 9% of all cases of blindness worldwide. In Germany, half of all cases of blindness and high-grade visual impairment are due to AMD. The number of persons with early AMD in Germany rose from 5.7 million in 2002 to ca. 7 million in 2017. Late AMD is subdivided into the dry late form of the disease, for which there is no treatment at present, and the exudative late form, which can be treated with the intravitreal injection of VEGF inhibitors. In patients with a later stage of AMD, neovascular AMD is 1.4 times more common than geographical atrophy (the final stage of dry late AMD). The rising prevalence figures may be due not only to the aging of the population, but also to better ascertainment through improved diagnosis. The major effect of age on the emergence of AMD is also reflected in the fact that persons under age 50 generally display very few of the typical changes of AMD, or none at all. The exudative form of late AMD is usually associated with much more rapidly progressive loss of vision than the atrophic form. The visual loss in the exudative form is explained by the development of choroidal neovascularization (CNV) in the macular area. The introduction, in 2005, of an effective treatment for the most aggressive form of AMD, the exudative late form, has led to a stagnation, or even a decrease, in the rates of blindness and severe visual impairment, even though the prevalence of AMD has measurably risen. In 2006, after the publication of two successful phase 3 clinical trials, the journal Science listed anti-VEGF therapy for exudative macular degeneration as one of the top ten scientific breakthroughs of the year. In this form of treatment, an anti-VEGF drug is injected directly in the vitreous body of the eye (intravitreal administration). Although the various anti-VEGF drugs differ from one another, they share a common mechanism of action, i.e., the blocking of vascular endothelial growth factor (VEGF). Much of the effect of VEGF inhibitors against wet macular degeneration comes from the reduction of vessel permeability, rather than from the inhibition of angiogenesis. AMD is a chronic disease in which the responsible pathogenetic-mechanistic cascade cannot be brought to a standstill with causally directed treatment early on in the course of illness, even in the stages for which effective treatment is available.

• #73 Age-Related Macular Degeneration – EyeWiki

  https://eyewiki.org/Age-Related_Macular_Degeneration

  The complement factor 3 inhibitor pegcetacoplan has been assessed for the treatment of the geographic atrophy in the phase 3 DERBY and OAKS trials. […] The first bi-specific antibody therapy for the treatment of neovascular AMD was recently approved by the FDA on January 31, 2022. Faricimab (Vabysmo, Genentech, San Francisco, CA) is a bi-specific antibody directed against both VEGF and angiopoietin-2.

• #74 Age-Related Macular Degeneration – EyeWiki

  https://eyewiki.org/Age-Related_Macular_Degeneration

  The complement factor 3 inhibitor pegcetacoplan has been assessed for the treatment of the geographic atrophy in the phase 3 DERBY and OAKS trials. […] The first bi-specific antibody therapy for the treatment of neovascular AMD was recently approved by the FDA on January 31, 2022. Faricimab (Vabysmo, Genentech, San Francisco, CA) is a bi-specific antibody directed against both VEGF and angiopoietin-2.

• #75 Age-Related Macular Degeneration—Wet Forms Including Macular Neovascularization

  https://www.asrs.org/patients/retinal-diseases/44/age-related-macular-degeneration-wet-forms-including-macular-neovascularization

  Wet-AMD treatment has been revolutionized in recent years after the discovery of vascular endothelial growth factor (VEGF), a family of compounds in the body. […] Anti-VEGF drugs have been developed to help control neovascularization and preserve vision for AMD patients. […] Wet AMD cannot be cured, but its progression may be blocked with the use of intravitreal (in-the-eye) anti-VEGF injections. […] Anti-VEGF drugs have greatly improved wet-AMD treatment since 2005; patients today have a much better chance of maintaining their central vision so they can read, drive, recognize faces, and live normal lives.

• #76 Age-related Macular Degeneration (AMD): A Review on its Epidemiology and Risk Factors

  https://openophthalmologyjournal.com/VOLUME/13/PAGE/90/FULLTEXT/

  During a five-year study in Australia, the incidences of early AMD among people younger than 60 years and more than 80 years were estimated to be 13% and 20%, respectively. […] The advanced levels of AMD are categorized into two forms: non-neovascular (dry, non-exudative or geographical) and neovascular (wet or exudative) AMD. […] In wet-type AMD, choroidal neovascularization leads to subretinal leakage of blood, lipids, fluids, and formation of fibrous scars. […] In spite of significant advancements associated with diagnostic and treatment methods of AMD, further investigations are needed to identify effective therapies for dry forms of AMD and reduce the injection frequency of anti-VEGF compounds for wet AMD. […] Although there is no single preventive method, alteration of modifiable risk factors can effectively impede the development of AMD. […] Both genetic and environmental risk factors are influential in the occurrence of AMD.

Zobacz więcej